Views & Analysis Exclusive: Brexit likely to cause long-term damage to UK pha... Exclusive survey finds concerns about future of UK pharma industry
Debates & Insight Sponsored Finding a cure: Getting the best Brexit deal for Britain’s l... Four months have now elapsed since the UK voted to leave the EU.
News J&J jumps on the MFN pricing train Johnson & Johnson is the latest pharma group to agree a Most-Favoured Nation (MFN) drug pricing deal with the Trump administration to avert tariffs.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
